Daily Cardiology Research Analysis
Analyzed 128 papers and selected 3 impactful papers.
Summary
Analyzed 128 papers and selected 3 impactful articles.
Selected Articles
1. Bclaf1 drives heart failure by recruiting Srsf2 to enhance Hand2 pre-mRNA splicing and pathological hypertrophy.
This mechanistic study shows that Bclaf1 recruits Srsf2 to enhance Hand2 splicing, driving maladaptive hypertrophy and systolic dysfunction. Genetic loss or AAV9 knockdown of Bclaf1, or inhibition of Hand2, reverses heart failure phenotypes, nominating a tractable splicing axis for therapy.
Impact: Identifies a previously unrecognized splicing control pathway as a proximal driver of HFrEF with bidirectional genetic validation in human tissue and mouse models.
Clinical Implications: While preclinical, targeting the Bclaf1/Srsf2/Hand2 axis (e.g., antisense or small molecules) could inaugurate mechanism-based therapies for HFrEF beyond neurohormonal blockade.
Key Findings
- Bclaf1 is upregulated in human HFrEF myocardium and murine pressure-overload hearts.
- Cardiac-specific Bclaf1 overexpression induces pathological hypertrophy and systolic dysfunction; knockout or AAV9 knockdown attenuates these phenotypes.
- Bclaf1 interacts with Srsf2 to enhance Hand2 pre-mRNA splicing, increasing mature Hand2 and promoting maladaptive remodeling.
- Pharmacologic/genetic inhibition of Bclaf1 or Hand2 rescues cardiac structure and function in experimental HFrEF.
Methodological Strengths
- Human-mouse translational design with human HFrEF myocardium validation and multiple in vivo genetic perturbations.
- Mechanistic dissection of RNA splicing via protein–protein interaction and target pre-mRNA engagement, with rescue experiments.
Limitations
- Predominantly male murine models; sex-specific effects and long-term safety of targeting this axis remain unknown.
- Preclinical study without large-animal validation or pharmacokinetic/toxicology data.
Future Directions: Develop antisense/chemical probes to modulate Bclaf1–Srsf2–Hand2 splicing in large-animal HFrEF models; biomarker strategies to identify splicing-driven HF endotypes for trials.
Heart failure with reduced ejection fraction (HFrEF) remains a major therapeutic challenge. B-cell lymphoma 2-associated transcription factor 1 (Bclaf1) is implicated in RNA splicing and cardiac disease, but its role in HFrEF pathogenesis is unknown. Here, we demonstrate that Bclaf1 expression is elevated in human HFrEF myocardium and in male murine pressure-overload models. Cardiac-specific Bclaf1 overexpression drives pathological hypertrophy and systolic dysfunction, whereas its genetic knockout or adeno-associated virus serotype 9 (AAV9)-mediated knockdown attenuates these phenotypes. Mechanistically, Bclaf1 interacts with the splicing factor serine/arginine-rich splicing factor 2 (Srsf2) to bind to heart and neural crest derivatives expressed 2 (Hand2) pre-mRNA and enhance its splicing efficiency, leading to increased mature Hand2 levels and maladaptive remodeling. Inhibition of either Bclaf1 or Hand2 rescues cardiac function and structure in experimental HFrEF. Our work defines a Bclaf1/Srsf2/Hand2 splicing axis as a critical driver of HFrEF and reveals a promising therapeutic target for heart failure.
2. Fate-mapping infiltrating monocytes following experimental myocardial infarction revealsdifferentiation trajectories in the infarcted heart.
Using CCR2-driven lineage tracing with scRNA-seq, the study delineates two major monocyte-to-macrophage trajectories after reperfused MI, partitioned to the border and infarct zones. A type I interferon–responsive intermediate macrophage subset induces Tregs and promotes myocardial protection, suggesting therapeutic leverage of monocyte fate.
Impact: Provides high-resolution fate maps linking spatially defined macrophage programs to reparative immunity after MI, identifying a protective interferon-responsive intermediate.
Clinical Implications: Therapies that bias monocyte differentiation toward interferon-responsive/Treg-inducing macrophages may improve post-MI healing and reduce adverse remodeling.
Key Findings
- CCR2-lineage tracing with scRNA-seq reveals transcriptionally distinct, spatially restricted macrophage and DC-like subsets persisting chronically post-MI.
- Pseudotime analysis identifies two monocyte-to-macrophage trajectories segregated to the border vs infarct zones.
- A type I interferon–responsive intermediate macrophage subset gives rise to MHC-IIhi macrophages, localizes to the border zone, induces Tregs, and promotes myocardial protection.
Methodological Strengths
- Genetic fate mapping combined with single-cell transcriptomics and spatial localization in a reperfused MI model.
- Functional linkage of interferon-responsive macrophages to Treg induction and myocardial protection.
Limitations
- Preclinical murine study; human validation of identified macrophage subsets and trajectories is needed.
- Causal pathway components beyond interferon signaling require further mechanistic dissection.
Future Directions: Validate macrophage trajectories and IFN-responsive intermediates in human MI; test cytokine/agonist/biologic strategies to skew monocyte fate toward reparative programs.
Inflammation contributes to the pathogenesis of myocardial infarction and heart failure and represents a viable therapeutic target. Monocytes and their progeny are highly abundant and display striking functional diversity, serving as key determinants of myocardial inflammation and tissue repair. Much remains to be learned regarding mechanisms and signaling events that instruct monocyte fate decisions. We devised a genetic lineage tracing strategy using Ccr2crERT2Rosa26LSL-tdTomato mice in combination with single cell RNA-sequencing to map the differentiation trajectories of monocytes that infiltrate the heart after reperfused myocardial infarction. Monocytes were recruited to the heart early after injury and gave rise to transcriptionally distinct and spatially restricted macrophage and dendritic cell-like subsets that were specified prior to extravasation and chronically persisted within the myocardium. Pseudotime analysis predicted two differentiation trajectories of monocyte-derived macrophages that are partitioned into the border and infarct zones, respectively. Among these trajectories, we demonstrated that macrophages expressing a type I interferon responsive signature were an intermediate population that gave rise to MHC-IIhi macrophages, were localized within the border zone, induce regulatory T cells, and promote myocardial protection. Collectively, these data uncover complexities of monocyte differentiation in the infarcted heart and suggest that modulating monocyte fate decisions may have clinical implications.
3. Comparative Effectiveness and Safety of Interventions for Atrial Fibrillation in Heart Failure: A Network Meta-Analysis of Randomized Trials.
Across 23 RCTs in HF with AF, AV node ablation with CRT and catheter ablation reduced all-cause mortality versus conventional care. AVNA with CRT outperformed RV pacing for HF hospitalization/worsening HF, while catheter ablation improved quality of life and LVEF compared with medical rhythm control.
Impact: Synthesizes randomized evidence to clarify strategy selection in a prevalent, high-risk population, offering practice-informing comparative effectiveness signals.
Clinical Implications: For HF with AF, consider catheter ablation when feasible for survival and QoL benefits; if AV node ablation is chosen, pair with CRT rather than RV pacing to reduce HF events.
Key Findings
- AV node ablation with CRT reduced all-cause mortality versus conventional care and versus AVNA with RV pacing.
- Catheter ablation reduced all-cause mortality versus conventional care and improved QoL and LVEF versus medical rhythm control.
- AVNA with CRT lowered HF hospitalization and worsening HF compared with AVNA with RV pacing; CV mortality differences were not clearly demonstrated.
Methodological Strengths
- Network meta-analysis restricted to randomized trials with multiple strategies compared and SUCRA-based ranking.
- Assessment of mortality, HF events, QoL, and LVEF across 23 trials (n=5,159).
Limitations
- Heterogeneity in trial populations, rhythm strategies, and follow-up; potential inconsistency across networks.
- Risk-of-bias assessments and PRISMA details not specified; some endpoints derived from fewer trials.
Future Directions: Head-to-head RCTs comparing catheter ablation versus AVNA+CRT in phenotype-defined HF+AF; cost-effectiveness and patient-centered outcomes to guide individualized strategy.
BACKGROUND: Patients with HF and AF face high risks of death and HF decompensation, yet the comparative effectiveness of commonly used AF management strategies remains uncertain. This study is aimed at comparing the efficacy and safety of different interventional and medical approaches using NMA of RCTs. METHODS: PubMed, Embase, CENTRAL, Web of Science, and Google Scholar were searched from inception to November 30, 2025, without language restrictions. Parallel-group RCTs enrolling adults with clinically diagnosed HF and documented AF were eligible if they compared at least two AF management strategies, including CA, AVNA with CRT or RV pacing, MRC, drug-based rhythm control (rhythm drug), or CON. Primary outcomes were all-cause mortality and HF hospitalization; secondary outcomes were worsening HF, CV mortality, QoL, and LVEF. Random-effects NMA was performed in Stata 17.0, reporting ORs and SMDs with 95% CIs; treatments were ranked using SUCRA. RESULTS: Twenty-three RCTs (5159 patients) were included. For all-cause mortality (21 trials; 5095 patients), AVNA_CRT (OR, 0.30; 95% CI, 0.12-0.78) and CA (OR, 0.53; 95% CI, 0.35-0.82) were associated with lower mortality than CON; AVNA_CRT also outperformed MRC (OR, 0.35; 95% CI, 0.15-0.79) and AVNA_RV (OR, 0.49; 95% CI, 0.25-0.96). For HF hospitalization (9 trials; 3491 patients), AVNA_CRT reduced risk compared with AVNA_RV (OR, 0.20; 95% CI, 0.04-0.94). For worsening HF (7 trials; 2542 patients), AVNA_CRT was superior to AVNA_RV (OR, 0.41; 95% CI, 0.20-0.84). CA improved QoL versus AVNA_CRT (SMD, -0.94; 95% CI, -1.83 to -0.05) and MRC (SMD, -0.73; 95% CI, -1.22 to -0.24), and improved LVEF versus MRC (SMD, 1.49; 95% CI, 0.57-2.41). No between-strategy differences were clearly demonstrated for CV mortality. CONCLUSION: In RCT evidence for HF with AF, AVNA_CRT and CA were associated with more favorable prognostic outcomes, and CA provided more consistent improvements in QoL and LVEF. When AVNA is selected, CRT should be preferred over RV pacing. Strategy choice should be individualized to clinical goals, patient phenotype, and procedural feasibility.